Today’s AI Top Pick: TMDX

7/31/2026 · Highly Shorted High Growth Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Highly Shorted High Growth Deep RotationTMDXBUY NOW8.8 / 107/31/2026

TransMedics (TMDX) is the cleanest setup in the pool where fundamentals and the tape agree. On the fundamentals side it passes the screen with room to spare: PE 17.47 / fwdPe 24.81, ROE 45.22%, profit margin 27.04%, sales growth 30.24% Y/Y, EPS growth next year 67.77%, recom 1.75, and an analyst target upside of +44%. That's real profitability — not a 'story stock' with -50% operating margins like most of the other high-shorted names on this list. The forecast tape is where TMDX separates from the pack. Multi-timeframe alignment is essentially unanimous to the upside: 1h fc_short/mid/long +23.5% / +28.4% / +28.2%, 4h +37.4% / +24.1% / +31.1%, 1d +21.1% / +51.6% / +37.8%, and even the 1wk turns positive out the curve (+19.9% long) after a brutal -37.26% 21-bar drawdown. Near_term_bullish is a maxed 1.0 with bullish_prob 1.0. Crucially, while the 1h/4h/1d position_in_21bar_range is elevated (75–94%), the WEEKLY position is only 23.68% with dd_from_21bar_high -37.26% — meaning we're bouncing off a deeply oversold weekly base, not chasing an extended weekly leg. That's the ideal 'coiled spring' geometry. Headlines are supportive, not concerning: ChartMill flagged it as 'affordable growth with strong earnings momentum' on 7/28, and prior analyst target cut is now old news (7/8) — the tape has since put in a higher low. There is no dilution, no short-seller report, no guidance cut. Compare that to PHAT (worst day in 18 months on 7/30), MNDY (20% layoffs), CELH (earnings 8/6 = binary event), or KLAR (forecasts negative across daily). TMDX gives you a >40% analyst upside, a profitable growing MedTech, oversold on the long timeframe, with all near-term forecasts pointing up double-digits. Waiting risks missing the base breakout — buy today with a stop under the recent higher-low structure.

Entry zone

$76.00–$78.00 (current $77.48; scale in on any intraday dip to the $76 handle)

Stop loss

$71.50 (below the 4h/1d recent structure and ~7.7% risk; a break here invalidates the base-recovery thesis)

First target

$88–$92 (aligns with 1h/4h fc_short/mid +21–28% and covers the immediate gap-fill zone)

Longer target

$105–$118 (1d fc_mid +51.63% / fc_long +37.75% and analyst target upside +44% → ~$111)

Risks

Short-term position_in_21bar_range is elevated (1d 94.27%, 4h 90.3%) — a 3–5% mean-reversion pullback is possible before the next leg
Short float 23.23% cuts both ways: fuels squeezes but amplifies downside if forecasts break
Debt/Equity 1.75 is on the higher side for a MedTech; any capital-raise headline would hit hard
Weekly still shows -37.26% 21-bar drawdown — the primary trend is only just turning, not confirmed
Sector-adjacent earnings (RXST preview mentioned decline) could create MedTech risk-off spillover

Honorable mentions

BKVBest pure-fundamentals name (PE 7.29, ROE 15.9%, profit margin 27.9%, PEG 0.71, recom 1.23). 1h/4h/1d forecasts all positive (+16/+15/+18, +13/+23/+14, +3/+9/+8) with 1d position only 20.54% — not chasing. Slightly less forecast magnitude than TMDX and no weekly data, so it's #2.

MPMassive multi-TF forecasts (1h +45/+50/+53, 4h +38/+38/+37, 1d +6/+35/+32), Goldman 'mine-to-magnet' AI narrative on 7/31, position 33% on daily. Held back by -20% profit margin and negative weekly forecast (-24% long), making it more of a trade than an investment.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	TMDX	BUY NOW	8.8	Profitable growth MedTech with unanimous 1h/4h/1d bullish forecasts (+21–52%) bouncing off a -37% weekly base.
2	BKV	BUY NOW	8.0	Cheapest name in the pool (PE 7.29) with positive forecasts across every available TF and low range-position (20.5% on 1d).
3	MP	BUY NOW	7.6	Rare-earth AI beneficiary with +30–50% forecasts and Goldman tailwind; watch the negative weekly forecast.
4	BIRK	BUY PULLBACK	7.0	Solid fundamentals (16% margin, 24.5% oper margin, PEG 0.94) but forecasts are muted (+2–7%) — wait for lower entry.
5	ADTN	BUY PULLBACK	6.9	Deeply oversold (RSI 23.21, 1wk position 0%) with monster 1h/4h forecasts (+61–87%) but weak daily follow-through.
6	FOUR	BUY PULLBACK	6.7	Weekly forecast strong (+9–30%) and fwdPe 7.91 attractive, but 1h forecasts negative and 1wk position 100% — chase risk.
7	DUOL	BUY PULLBACK	6.5	Best profitability in pool (38.44% margin, ROE 37%) with 1d/1wk forecasts +13–38%, but recom 2.85 and target upside -14.1% are red flags.
8	MNDY	WAIT	6.2	Daily forecast +27–56% is elite but 20% layoffs headline and 1wk position 100% suggests wait for retest.
9	CELH	WAIT	6.0	Great fundamentals block but Q2 earnings 8/6 is a binary event and near_term_bullish only 0.4.
10	PGY	WAIT	5.8	Strong fundamentals (PEG 0.19, recom 1.0) but 1h/4h forecasts are decisively negative (-17 to -19%).
11	TTAN	WAIT	5.5	Just jumped 7.4% and forecasts turning negative (-11 to -18%) on 1h/4h — momentum exhausted.
12	KVYO	BUY PULLBACK	5.4	Daily/weekly forecasts +11–46% and recom 1.17, but near_term_bullish only 0.4 and no earnings yet.
13	PHAT	WAIT	5.3	Enormous forecasts (+19–45%) but 'worst day in 1.5 years' 7/30 selloff makes this a knife-catch.
14	TNXP	BUY PULLBACK	5.2	Medicare coverage win + oversold, but weekly forecast +50000% is a broken outlier, discount that.
15	ASPI	BUY PULLBACK	5.0	1h/4h/1d forecasts +34–70% and Noble Africa catalyst, but 1wk forecasts sharply negative (-15 to -40%).
16	BTDR	WAIT	4.8	Sales growth 146% but 43.35% short float and negative long-term weekly forecast (-22%) — crowded short trade.
17	HIVE	WAIT	4.7	Chardan buy $7.50 target and AI narrative, but 4h and 1wk forecasts negative — signal conflict.
18	RDW	BUY PULLBACK	4.6	1h forecasts +74–82% but 4h/1d/1wk decay quickly; deep 64% weekly drawdown = falling knife risk.
19	ASST	WAIT	4.5	Bitcoin treasury play with +33–62% daily forecasts but PS 174.5 and -12110% profit margin — pure speculation.
20	PDYN	WAIT	4.3	USAF contract catalyst and 1h/4h/1d bullish, but weekly forecasts decisively negative (-25 to -37%).
21	ABAT	BUY PULLBACK	4.2	DOE grant reinstated and massive 4h forecasts (+60–93%) but weekly still bleeding, need base.
22	PROP	AVOID	4.0	Debt/Equity 1222, ROE -700%, penny stock at $0.74 with -62% weekly move — screen artifact.
23	INV	AVOID	3.8	PS 85.07, -5226% profit margin, $3.47 microcap — forecasts irrelevant without a real business.
24	KLAR	AVOID	3.6	Daily forecasts -6 to -23% despite Apple leasing catalyst; tape is telling you news is priced in.
25	MUX	AVOID	3.5	Fundamentals solid but 1wk forecasts -13 to -51% and near_term_bullish 0.0 — broken tape.
26	UUUU	WAIT	3.4	White Mesa expansion positive, but 1h position 100% and long-horizon forecasts modest.
27	VIA	AVOID	3.0	1h forecasts -30 to -35% and 1d -5 to -13%, with no bullish_prob data — signal broken.
28	KULR	AVOID	2.8	Selling 333 BTC on 7/24 = dilution proxy; 1d/1wk forecasts turning negative.
29	CRWV	AVOID	2.5	Insider selling 7/30, debt/equity 7.39, and Aschenbrenner secondary — governance red flags.
30	DLO	AVOID	2.0	bullish_prob 0.0 and expected_return_pct -20.9% — model is explicitly telling you not to buy.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord